Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
March 14, 2024 02:00 ET
|
Anocca AB
NEW YORK and SÖDERTÄLJE, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, and EmendoBio Inc....
Anocca Appoints Martin Welschof to Board of Directors
February 13, 2024 03:00 ET
|
Anocca AB
SÖDERTÄLJE, Sweden, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading TCR-T1 cell therapy company, today announced the appointment of Martin Welschof to its Board of Directors. ...
Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development
January 04, 2024 03:00 ET
|
Anocca AB
SÖDERTALJE, Sweden, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading TCR-T1 cell therapy company, today announced it has received a certificate of good manufacturing practice (GMP)...
Anocca raises SEK 400 million for large-scale development of cancer cell therapies
May 31, 2023 01:30 ET
|
Anocca AB
SÖDERTÄLJE, Sweden, May 31, 2023 (GLOBE NEWSWIRE) -- Anocca AB today announces that the company has successfully raised SEK 400 million through an equity financing round led by AMF and...